



PRESS RELEASE

ASLAN PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT ON EBLASAKIMAB AND NEURONAL ITCH MECHANISMS FOR POSTER PRESENTATION AT THE 2022 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING

Menlo Park, California, and Singapore, May 10, 2022 – ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract highlighting new data and insights related to neuronal itch mechanisms through *eblasakimab*'s targeting of IL-13R α 1 has been accepted for late-breaking poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting, to be held in-person from May 18 to 21, 2022, in Portland, Oregon.

Ferda Cevikbas PhD, Head of Translational Sciences at ASLAN, will present findings from an *ex vivo* study in human dorsal root ganglia neurons which showed a significant inhibitory effect of *eblasakimab* on the IL-4 and IL-13 enhanced sensitization of neuronal itch responses. IL-4 and IL-13 are central to the pathogenesis of atopic dermatitis, exacerbate inflammation and exert neuronal enhancer function to itch. Targeting the IL-13R α 1 blocks IL-4 and IL-13 signaling through the Type 2 receptor and could provide a differentiated approach to disrupt the inflammation and heightened itch experienced by AD patients.

2022 Society for Investigative Dermatology Annual Meeting poster details

Title: *New insights into neuronal itch mechanisms by targeting IL-13R α 1 with eblasakimab*

Presentation date and time: Poster Session 1, Thursday, May 19, 2022, 4:30 - 6:30PM ET

Presenter: Dr Ferda Cevikbas, Head Translational Sciences, ASLAN Pharmaceuticals

Location: Oregon Convention Centre, Exhibit Hall A/A1/B

Abstract number: LB1039

The poster will be available to view online in the Investor Relations section of ASLAN's website following presentation: <https://ir.aslanpharma.com/>.

About *eblasakimab*

Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor, with the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen for patients. In September 2021, ASLAN announced positive results from the Phase 1b multiple-ascending-dose study that established proof-of-concept of ASLAN004 and supported its potential as a novel treatment for AD.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating *eblasakimab*, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and *farudodstat*, a potent oral inhibitor of the enzyme, DHODH, in autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on [LinkedIn](#).

Ends



Media and IR contacts

Emma Thompson

Spurwing Communications

Tel: +65 6206 7350

Email: ASLAN@spurwingcomms.com

Ashley R. Robinson

LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email: arr@lifesciadvisors.com